Latest News
Latest Events
Home Media Center
1 U.S.A.: INITIATION OF PHASE II TRIAL OF PONATINIB IN PATIENTS WITH GIST
2 EMA will review a marketing authorization application for Masitinib in the treatment of Imatinib resistant GIST
3 ASCO 2012: Three Presentations Detailing the Results of Masitinib in the Treatment of Advanced GIST
4 SPAEN Press Release: SPAEN regrets the released information from AB Science: “Masitinib significantly extends overall survival as second-line drug for GIST…”
5 SPAEN Newsletter May 2012
6 SPAEN Newsletter April 2012
7 SPAEN Newsletter March 2012
8 SPAEN Press Release: SPAEN regrets the released information from AB Science: “Masitinib significantly extends overall survival as second-line drug for GIST…”
9 SPAEN Newsletter February 2012
10 SPAEN Newsletter August 2011
11 SPAEN Newsletter June 2011
12 ASCO 2011 News: Ridaforolimus Achieved Primary Endpoint of Improved Progression-Free Survival (PFS) in Metastatic Soft-tissue or Bone Sarcomas
13 SPAEN Info ASCO 2011 News: Pazopanib improved progression free survival in adults with certain soft tissue sarcomas
14 SPAEN Info ASCO 2011 News: 36 months adjuvant Imatinib-treatment for high-risk-GISTs improves recurrence-free survival (RFS) and even overall survival (OS)
15 SPAEN Newsletter May 2011
16 SPAEN Newsletter April 2011
17 SPAEN Information 11/04/2011 GIST Nilotinib ERNESTg1 Trial
18 SPAEN Newsletter March 2011: SPAEN Website launched
19 SPAEN Newsletter February 2011
20 Press Release SPAEN Foundation November 2008
 
Member LogIn



Copyright: SPAEN Sarcoma Patients EuroNet © 2011